RAAS profit slumps, but pipeline and buyback offer support
First-half profit and revenue fall sharply First-half revenue fell 18.79% and net profit dropped 35.8% from a year earlier, with no dividend paid. The whole blood-products industry was weak, and the company carries 8.2 billion yuan of goodwill from past deals, which could hurt earnings if business stays soft.
This is the main force pushing the stock down, showing weaker earnings and balance-sheet risk.
New drug pipeline advances toward market A Phase II trial started for SR604, a first-in-class hemophilia antibody, and it has now entered Phase III. A Protein C trial application was also accepted. These could widen the product line and improve plasma use, though no revenue yet.
Pipeline progress is the main positive driver that could lift future growth and investor sentiment.
Company buys back its own shares RAAS repurchased 17 million shares for about 85.7 million yuan, roughly 0.26% of total shares. Buybacks reduce shares outstanding and signal management sees value, giving some support to the stock price.
The buyback is a concrete capital action that supports the share price.
CFO departure adds uncertainty Chief financial officer Chen Leqi resigned for personal reasons and was replaced by Jiang Lan, who spent over twenty years in the Haier system. A finance chief change during weak results can worry investors about internal stability.
Leadership change at the finance helm is a real counterweight to the positive pipeline news.